1. Academic Validation
  2. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles

  • J Med Chem. 2014 Jan 23;57(2):325-38. doi: 10.1021/jm4016747.
David J St Jean Jr 1 Kate S Ashton Michael D Bartberger Jie Chen Samer Chmait Rod Cupples Elizabeth Galbreath Joan Helmering Fang-Tsao Hong Steven R Jordan Longbin Liu Roxanne K Kunz Klaus Michelsen Nobuko Nishimura Lewis D Pennington Steve F Poon Darren Reid Glenn Sivits Markian M Stec Seifu Tadesse Nuria Tamayo Gwyneth Van Kevin C Yang Jiandong Zhang Mark H Norman Christopher Fotsch David J Lloyd Clarence Hale
Affiliations

Affiliation

  • 1 Department of Therapeutic Discovery-Medicinal Chemistry, ‡Department of Therapeutic Discovery-Molecular Structure and Characterization, §Department of Metabolic Disorders, ∥Department of Pharmacokinetics and Drug Metabolism, ⊥Department of Pathology, #Department of Pharmaceutics Amgen, Inc. , One Amgen Center Drive, Thousand Oaks, California, 91320 and 360 Binney Street, Cambridge, Massachusetts, 02142, United States.
Abstract

In the previous report , we described the discovery and optimization of novel small molecule disruptors of the GK-GKRP interaction culminating in the identification of 1 (AMG-1694). Although this analogue possessed excellent in vitro potency and was a useful tool compound in initial proof-of-concept experiments, high metabolic turnover limited its advancement. Guided by a combination of metabolite identification and structure-based design, we have successfully discovered a potent and metabolically stable GK-GKRP disruptor (27, AMG-3969). When administered to db/db mice, this compound demonstrated a robust pharmacodynamic response (GK translocation) as well as statistically significant dose-dependent reductions in fed blood glucose levels.

Figures
Products